Tenofovir News and Research

RSS
Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

No effect of baseline cirrhosis on long-term TDF treatment outcomes

No effect of baseline cirrhosis on long-term TDF treatment outcomes

US health care providers reluctant to prescribe HIV prevention plan

US health care providers reluctant to prescribe HIV prevention plan

Long-term entecavir, TDF effective in chronic HBV in real-world setting

Long-term entecavir, TDF effective in chronic HBV in real-world setting

HBV genotype C HBeAg seroconversion rate ‘negligible’

HBV genotype C HBeAg seroconversion rate ‘negligible’

WHO releases first-ever guidance for chronic hepatitis B treatment

WHO releases first-ever guidance for chronic hepatitis B treatment

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

HIV Prevention Trials Network launches two phase 2 studies to evaluate new HIV drugs

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

NIH-sponsored clinical trials examine safety, acceptability of HIV antiretroviral medicines

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

TDF monotherapy ‘reasonable’ option in entecavir-resistant HBV

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Long-term TDF ‘promising’ in Chinese HBV patients after multiple antiviral failures

Tenofovir stems treatment-induced kidney toxicity in HBV-related chronic hepatitis

Tenofovir stems treatment-induced kidney toxicity in HBV-related chronic hepatitis

Long-term TDF therapy offers sustained HBV suppression without resistance

Long-term TDF therapy offers sustained HBV suppression without resistance

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection

MSD announces Phase 2b results of doravirine therapy in untreated patients with HIV-1 infection